Pharma Marketing: Pretty Much the Same As Every Other Kind of Marketing

For indispensable reporting on the coronavirus crisis, the election, and more, subscribe to the Mother Jones Daily newsletter.


Charles Ornstein and Ryann Grochowski Jones published a story yesterday that’s gotten a lot of attention. It’s an examination of where pharmaceutical companies spend most of their marketing budgets:

The drugs most aggressively promoted to doctors typically aren’t cures or even big medical breakthroughs. Some are top sellers, but most are not. Instead, they are newer drugs that manufacturers hope will gain a foothold, sometimes after failing to meet Wall Street’s early expectations.

“They may have some unique niche in the market, but they are fairly redundant with other therapies that are already available,” said Dr. Joseph Ross, an associate professor of medicine and public health at Yale University School of Medicine. “Many of these, you could call me-too drugs.”

Maybe this is just my marketing background blinding me to an obvious outrage, but….what else would you expect? This is what every company does. If you’re in marketing, you spend a lot of money on new product launches and you spend a lot of money where you most need to differentiate yourself. This is nothing unique to pharma. It’s just the common-sense way that marketing works.

There’s a lot that’s wrong with pharmaceutical R&D priorities, and there’s also a lot that’s wrong with pharmaceutical marketing strategies. But spending a lot of money on new products that have entrenched competitors? If that’s wrong, then every consumer products company on the planet is doing something wrong. I’m a bit at a loss to figure out what the story is supposed to be here.

DOES IT FEEL LIKE POLITICS IS AT A BREAKING POINT?

Headshot of Editor in Chief of Mother Jones, Clara Jeffery

It sure feels that way to me, and here at Mother Jones, we’ve been thinking a lot about what journalism needs to do differently, and how we can have the biggest impact.

We kept coming back to one word: corruption. Democracy and the rule of law being undermined by those with wealth and power for their own gain. So we're launching an ambitious Mother Jones Corruption Project to do deep, time-intensive reporting on systemic corruption, and asking the MoJo community to help crowdfund it.

We aim to hire, build a team, and give them the time and space needed to understand how we got here and how we might get out. We want to dig into the forces and decisions that have allowed massive conflicts of interest, influence peddling, and win-at-all-costs politics to flourish.

It's unlike anything we've done, and we have seed funding to get started, but we're looking to raise $500,000 from readers by July when we'll be making key budgeting decisions—and the more resources we have by then, the deeper we can dig. If our plan sounds good to you, please help kickstart it with a tax-deductible donation today.

Thanks for reading—whether or not you can pitch in today, or ever, I'm glad you're with us.

Signed by Clara Jeffery

Clara Jeffery, Editor-in-Chief

payment methods

We Recommend

Latest